Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Retained Earnings (2016 - 2025)

Ultragenyx Pharmaceutical has reported Retained Earnings over the past 11 years, most recently at $1.0 million for Q4 2025.

  • Quarterly Retained Earnings rose 200.0% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 200.0% year-over-year, with the annual reading at $1.0 million for FY2025, 200.0% up from the prior year.
  • Retained Earnings was $1.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $820000.0 in the prior quarter.
  • Over five years, Retained Earnings peaked at $1.0 million in Q4 2025 and troughed at -$4.1 billion in Q1 2025.
  • The 5-year median for Retained Earnings is -$1.8 million (2021), against an average of -$989.0 million.
  • Year-over-year, Retained Earnings crashed 1027721.98% in 2022 and then skyrocketed 200.0% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$1.4 million in 2021, then plummeted by 368.16% to -$6.6 million in 2022, then plummeted by 51439.04% to -$3.4 billion in 2023, then skyrocketed by 99.97% to -$1.0 million in 2024, then skyrocketed by 200.0% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Retained Earnings are $1.0 million (Q4 2025), $820000.0 (Q3 2025), and -$268000.0 (Q2 2025).